Joined in 2023 
82 
63 About this deal
Industry-Sponsored Symposium Exclusive Sponsor: This exclusive sponsorship will guarantee you your first choice of time/dates (from the AHS provided list). You will also receive extra promotions throughout the conference space. The American Headache Society ® designates this Other (live and recorded sessions) activity for a maximum of 34.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. The American Board of Psychiatry and Neurology has reviewed the 65 th Annual Scientific Meeting and has approved this activity as part of a comprehensive Continuing Medical Education (CME) program, which is mandated by the ABMS as a necessary component of Continuing Certification. Upsher-Smith Laboratories, LLC is a trusted U.S. pharmaceutical company striving to improve the health and lives of patients through an unwavering commitment to high-quality products and sustainable growth. For more information, visit www.upsher-smith.com. Congratulations to those abstracts accepted as posters! We know this is an exciting time and that you may have questions. Please read the FAQ’s below:
Assess what is known and unknown about understudied headache diseases, including tension-type headache, cervicogenic headache, and new daily persistent headache Dallas, TX Prolactin signaling modulates stress-induced behavioral responses in a preclinical mouse model of migraine Bianca N. Mason PhD, Rohini Kallianpur, Theodore J. Price PhD, Armen N. Akopian PhD, Gregory O. Dussor PhD The AAFP has reviewed 65th Annual Scientific Meeting (2023) and deemed it acceptable for up to 33.75 Live AAFP Elective credits. Term of Approval is from 06/15/2023 to 06/18/2023. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Join us during the AHS Membership Meeting on Thursday, June 15 from 4:45 – 5:30 PM CDT in Lone Star D-E for Above and Beyond, Distinguished Service, Basic Science Prize, and Members’ Choice award presentations.
Follow us on:
We’re a company that takes on the toughest health challenges. But we do more than treat diseases—we aim to make a remarkable impact on people’s lives. We are AbbVie, a highly focused research-driven biopharmaceutical company. If you aren’t a fan of arachnids or pregnancy-related horror stories, then I think it’s safe to say that this upcoming season of the horror anthology show created by Ryan Murphy and Brad Falchuk is not for you! They are available starting June 15, 2023 @ 12am CT. They will be published in the journal, Headache ® , as well as through the meeting’s mobile app.
All accepted abstract lead/presenting authors will receive a special set of instructions with their acceptance notice including information on how to register for the meeting. Join us on Friday, June 16 from 10:15 – 11:00 AM CDT in Lone Star D-E for the Seymour Solomon lecture and award presentation. Join us on Thursday, June 15 from 3:30 – 3:50 PM CDT in Lone Star D-E for the Early Career lecture and award presentation. For the American Headache Society’s corporate partners, The American Headache Society’s Annual Scientific Meeting continues to be the premiere venue for disseminating the latest and most up-to-date research and scientific advances underlying the practice of Headache Medicine.The American Headache Society ® is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Industry-initiated Research Involving Drugs, Devices, or other Products with a Commercial Interest. This category will not include investigator-initiated studies that may have industry support. Poster presenters with an ODD poster number should be available at their poster between 12:35 pm – 1:50 pm on Friday, June 16. Poster presenters with an EVEN poster number should be available between 12:45 pm – 2:00 pm on Saturday, June 17. Please note these times are scheduled during the lunch breaks for maximum attendee participation. You are not required to stand with your poster, but its a great opportunity to interact with attendees and answer questions they may have.
Palo Alto, CA The Efficacy of Rimegepant in the Treatment of Vestibular Migraine: A Single-Arm, Open-Label Study Accepted abstracts will be published in the journal, Headache ® . They are typically in the June edition or sent as a supplement to the June edition. Please note: The maximum number of credits is calculated based on attending all live sessions and then watching concurrent sessions as recordings later.Not yet. Only authors of (non-industry) abstracts chosen for oral presentations must complete a financial disclosure. All submitters will be asked to indicate if they have patient consent when including case-based data. Even Numbered Posters (i.e., P-02, P-26, P-108) should be hung on the assigned board between 5:00 pm – 7:00 pm on Friday, June 16 and removed by 2:00 pm on Saturday, June 17. Posters left after 2:00 pm may be discarded.
Great Deal 
New Comment